MEIRAGTX HOLDINGS PLC (MGTX) Stock Price & Overview
NASDAQ:MGTX • KYG596651029
The current stock price of MGTX is 7 USD. Today MGTX is up by 0.14%. In the past month the price decreased by -2.78%. In the past year, price increased by 9.72%.
MGTX Key Statistics
- Market Cap
- 563.43M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.11
- Dividend Yield
- N/A
MGTX Stock Performance
MGTX Stock Chart
MGTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MGTX. When comparing the yearly performance of all stocks, MGTX is a bad performer in the overall market: 72.71% of all stocks are doing better.
MGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MGTX. Both the profitability and financial health of MGTX have multiple concerns.
MGTX Earnings
On November 13, 2025 MGTX reported an EPS of -0.62 and a revenue of 410.00K. The company missed EPS expectations (-24.05% surprise) and missed revenue expectations (-94.22% surprise).
MGTX Forecast & Estimates
14 analysts have analysed MGTX and the average price target is 27.92 USD. This implies a price increase of 298.89% is expected in the next year compared to the current price of 7.
For the next year, analysts expect an EPS growth of -3.92% and a revenue growth 94.29% for MGTX
MGTX Groups
Sector & Classification
MGTX Financial Highlights
Over the last trailing twelve months MGTX reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS decreased by -2.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MGTX Ownership
MGTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MGTX
Company Profile
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is headquartered in New York City, New York and currently employs 409 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Company Info
MEIRAGTX HOLDINGS PLC
655 Third Avenue, Suite 1115
New York City NEW YORK 10016 US
CEO: Alexandria Forbes
Employees: 409
Phone: 16468607985
MEIRAGTX HOLDINGS PLC / MGTX FAQ
Can you describe the business of MEIRAGTX HOLDINGS PLC?
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is headquartered in New York City, New York and currently employs 409 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
What is the current price of MGTX stock?
The current stock price of MGTX is 7 USD. The price increased by 0.14% in the last trading session.
What is the dividend status of MEIRAGTX HOLDINGS PLC?
MGTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of MGTX stock?
MGTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for MEIRAGTX HOLDINGS PLC?
The Revenue of MEIRAGTX HOLDINGS PLC (MGTX) is expected to grow by 94.29% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for MEIRAGTX HOLDINGS PLC?
MEIRAGTX HOLDINGS PLC (MGTX) has a market capitalization of 563.43M USD. This makes MGTX a Small Cap stock.
What is the outstanding short interest for MEIRAGTX HOLDINGS PLC?
The outstanding short interest for MEIRAGTX HOLDINGS PLC (MGTX) is 9.69% of its float.